Mallinckrodt Plc - New Overview
Latest ROE for Mallinckrodt Plc - New: -45.43% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-45.43%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Mallinckrodt Plc - New (MNK) currently reports a ROE of -45.43%. That is below the Healthcare sector average of 21.67%. Use the charts on this page to explore Mallinckrodt Plc - New's ROE history and peer comparisons.
Mallinckrodt Plc - New's ROE of -45.43% is lower than the Healthcare sector average of 21.67%. That is roughly 309.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Mallinckrodt Plc - New's current -45.43% should be judged against Healthcare norms (sector average: 21.67%) and against MNK's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -45.43%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for Mallinckrodt Plc - New, and consider following MNK for alerts when major investors trade the stock.
Mallinckrodt Plc - New is classified in the Healthcare sector. On ROE, it currently shows -45.43% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MNK with unrelated industries.
